MetaCap

Artelo Biosciences (ARTL) vs GeoVax Labs (GOVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Artelo Biosciences is the larger company by market cap ($1.3 million vs $985,459), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTL-59.24%GOVX+525.43%
+682%+292%-97%
Oct 7, 20261 yearNov 20, 2026
ARTL-57.36%GOVX+544.13%
+574%+243%-87%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTL versus GOVX key metrics
MetricARTLGOVX
Share price$1.39$1.81
Market cap$1.30M$985.46K
1-day change-4.14%-5.24%
EPS (TTM)$-20.56$-15.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.49M
Revenue growth (YoY)—-37.06%
Net income (latest FY)$-12.88M$-21.46M
Operating margin—-869.34%
Net margin—-862.34%
52-week high$179.19$270.60
52-week low$1.30$1.51
Distance from 52-week high-99.22%-99.33%
Analyst consensus—none
Avg. price target upside—+452.49%
Average volume476.69K213.41K
Shares outstanding937.18K544.45K
Employees719
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Artelo Biosciences

ARTL stock →

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About GeoVax Labs

GOVX stock →

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

ARTL vs GOVX FAQ

Which is bigger, Artelo Biosciences or GeoVax Labs?

Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.30M compared with $985.46K for GeoVax Labs (GOVX).

Are Artelo Biosciences and GeoVax Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons